Call Us Sign-Up/Sign-In
Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Revive Therapeutics Files Business Acquisition Report


Revive Therapeutics

iCrowdNewswire   Feb 9, 2021  3:41 PM ET

 Revive Therapeutics Ltd., announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR) pursuant to National Instrument 51-102 Continuous Disclosure Obligations in connection with its acquisition of Psilocin Pharma Corp. on March 5, 2020.‎ The BAR has been filed as a result of a review conducted by staff at the Ontario Securities Commission in connection with the Company’s recently filed preliminary short form prospectus dated January 26, 2021.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com



Contact Information:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com








Tags:    Wire, Disclosure Newswire, United States, English